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Designed in collaboration with 23andMe and Pathway Genomics, the Impact of Personal Genomics (PGen) Study
serves as a model for academic-industry partnership and provides a longitudinal dataset for studying psychosocial,
behavioral, and health outcomes related to direct-to-consumer personal genomic testing (PGT). Web-based surveys
administered at three time points, and linked to individual-level PGT results, provide data on 1,464 PGT customers, of
which 71% completed each follow-up survey and 64% completed all three surveys. The cohort includes 15.7%
individuals of non-white ethnicity, and encompasses a range of income, education, and health levels. Over 90% of
participants agreed to re-contact for future research.Background
Nearly a decade after being introduced to the market,
commercial genomic profiling services, through which
consumers can independently obtain analysis and inter-
pretation of their genetic code, continue to fuel debate
among stakeholders regarding their clinical validity and
utility. Commercial offerings that were once covered by
the term ‘direct-to-consumer’ (DTC) genetic testing,
owing to their ‘pure’ model of direct access without clin-
ician involvement, have since diversified to encompass a
range of personal genomic testing (PGT) models with
varying levels of clinician involvement both before and
following testing [1]; nonetheless, the original criticisms
of the industry persist. Advocates argue that by facilitat-
ing direct access to an individual’s own genetic informa-
tion, PGT can promote democratization and autonomy
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unless otherwise stated.individuals to control the privacy and use of their per-
sonal genetic data [4]. Critics caution that risk informa-
tion from PGT could be misunderstood and lead to
anxiety, inappropriate self-treatment or unnecessary
utilization of health care services [5,6].
The call for empirical data on the impact of PGT
services has been widespread [7-10] and has resulted
in studies addressing such topics as public awareness
[11-13], consumer interest and motivations [14], results
comprehension [15,16], and physician awareness and
preparedness [17]. Only a few studies, however, have in-
volved actual PGT customers [18], and of these, many
have been limited by low response rates [19,20], small
sample sizes [19,21,22], an absence of baseline data col-
lection [19,23], service models that differ from current
commercial models [22,24-26], and an inability to link
participants’ responses to their PGT results [20,23]. Re-
search interest in PGT and its role in public health was
renewed in November 2013, when the United States
Food and Drug Administration (FDA) sent a Warning
Letter to 23andMe, Inc. ordering it to cease marketing
of its health-related PGT services until it received med-
ical device authorization [27].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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presents a considerable challenge. Without collaboration
between academia and industry, customers would be dif-
ficult to identify and contact, and specific details of the
PGT service could be inaccessible to investigators. The
Impact of Personal Genomics (PGen) Study is a longitu-
dinal study of PGT customers that was developed in
partnership with two PGT companies, 23andMe, Inc.
[28] (23andMe) and Pathway Genomics [29] (Pathway),
to evaluate customer motivations for purchasing PGT
and the effect of PGT risk information on psychological
status, risk perceptions and health behaviors. We have
previously reported on how we negotiated the ethical is-
sues associated with developing and maintaining a re-
search partnership between academia and industry in
planning the PGen Study [30]. Here, we present the sur-
veys themselves, and describe the protocol design and
data collection process, our survey response and reten-
tion rates, and the demographics and self-reported
health status of the PGen Study cohort.
Methods
Overview
The PGen Study was designed as a longitudinal series of
surveys (Figure 1) to measure the PGT experience at
three time points: baseline, after customers had ordered
PGT, but before they received their results (BL); approxi-
mately 2 weeks after receiving results (2 W); and ap-
proximately 6 months after receiving results (6 M).
Planning for the PGen Study was initiated in 2009 by aca-
demic researchers at Harvard Medical School in Boston,
Massachusetts and the University of Michigan School of
Public Health in Ann Arbor, Michigan. Industry collabora-
tors were sought from among the major PGT companies
operating at the time, and two (23andMe and Pathway)Figure 1 Timing of personal genomic testing (PGT) and survey data c
by solid arrows and bold text; data collection points are indicated by dasheagreed to participate. Details of how this partnership was
established, including a discussion of the ways in which its
inherent ethical challenges were addressed during the plan-
ning phase of the PGen Study, have been published previ-
ously [30]. Funding was received from the National Human
Genomic Research Institute in 2010, and approval was ob-
tained from Partners Human Research Committee and the
University of Michigan School of Public Health Institu-
tional Review Board.
Survey design
Academic and industry scientists participated in a two-day
retreat, followed by regular conference calls, to develop an
initial set of survey items. Questions were drawn from
validated measures of psychological states [31-33], health
behaviors [34,35], and numeracy [36]; and from previous
studies of PGT [36-40], genetics knowledge [41,42], and
numeracy [43]. Academic and company scientists, along
with expert consultants, were invited to propose additional
established or novel survey items, which were then
reviewed by the entire research team. Data collection inter-
ests of all parties were considered and balanced throughout
this process, in consultation with bioethics advisors.
Through pilot testing with cognitive interview tech-
niques, we refined the wording of certain questions, and
added or deleted questions to improve the length and
overall flow of the survey. The BL, 2 W, and 6 M surveys
were each designed to be completed in no more than
30 minutes to minimize respondent burden and enhance
response rates. Because customers of the two companies
received result disclosure reports that differed in both
style and content from each other, the PGen Study survey
questions were tailored to reflect the specific PGT experi-
ence of each company’s customers. For example, hypo-
thetical scenarios used in the 2 W survey were populatedollection in the PGen Study. Steps of the PGT process are indicated
d arrows and italicized text. BL, baseline; 2 W, 2 week; 6 M, 6 month.
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the company used by each participant, and BL and 6 M
survey questions were designed to reflect categories of re-
sults provided by the company that each participant had
utilized. Table 1 provides a summary of the items that ap-
peared in each survey. Variables measured in the PGen
Study encompassed four broad domains: personal charac-
teristics (for example, demographic information, genetic
literacy); personal health (for example, family medical his-
tory, health behaviors); health care outcomes (for example,
insurance status, utilization of medical screening services);
and behavioral responses to PGT (for example, perceived
utility of results, satisfaction with experience). Table 1 also
highlights items included in the 6 Month Non-Responder
(6 M-NR) survey, which was presented to 6 M survey
non-responders and is described in greater detail below.
Because PGT customers in our surveys received their
reports over the internet, a web-based survey was
selected for data collection. This approach leveraged the
benefits of web-based data collection - cost-efficient deliv-
ery of complex survey instruments; tailored content; and
maximization of participant confidentiality [44] - without
facing the usual concerns associated with this surveyTable 1 Variable measurement across three time points in th
Survey






Motivations and expectations +
Personal health
Personal and medical family history +
Health status and health behaviors +
Disease risk perceptions +
Conditions of interest +
Health care
Insurance status +
Use of medical screening services +
Use of medical diagnostic services
Responses to personal genomic testing
Sharing of genetic results +
Reactions to genetic results
Perceived utility of results
Use of genetic results
Information-seeking behaviors
Satisfaction with experience
A plus sign indicates measurement of variables within that specific category. aVaria
(6 M-NR) survey.administration method (that is, not reaching members of
the target population who are not regular internet users)
[45]. With the help of Survey Sciences Group, LLC (SSG,
Ann Arbor, MI, USA), each survey was programmed ac-
cording to established standards for web-based survey de-
sign, including screen layout, standard question formats,
and other visual design elements (for example, color,
graphics) [46,47]. Each survey was interactive, with navi-
gation buttons allowing respondents to move forward and
backward within the survey. Responses were saved each
time a navigation button was selected, permitting capture
of partially completed survey data and allowing respon-
dents to complete the survey in multiple sessions. Elec-
tronic timestamp capture enabled the research team to
record timing of survey initiation and completion, and cu-
mulative time spent across multiple sessions.
Following initial programming, each survey was thor-
oughly tested through well-established testing strategies
[48], including a web-based survey specifications docu-
ment to describe the intended design of the web survey
and to use as a tool in programmer testing; survey oper-
ations testing (that is, testing conducted by survey
system specialists unfamiliar with the PGen Studye PGen Study















bles in this category were also evaluated on the 6 Month Non-Responder
Carere et al. Genome Medicine 2014, 6:96 Page 4 of 11
http://genomemedicine.com/content/6/12/96questionnaires); and research team testing (that is, test-
ing by those familiar with the questionnaires, but not
the survey system). Usability assessments ensured that
the survey layout was intuitive and minimized risks to
data quality.
Participant recruitment and data collection
23andMe launched its service in November 2007, offer-
ing both ancestry and health-related information directly
to customers; the company continued with this model
until 22 November 2013, at which time provision of
health-related information to new customers was halted
after receiving an FDA Warning Letter. Pathway Gen-
omics entered the PGT market in 2008 with a similar
DTC service delivery model, but in 2010 modified their
model to require physician order. For the purposes of
enrollment in the PGen Study only, Pathway permitted
direct ordering of PGT by customers without external
physician referral, as described below.
Participant recruitment was restricted to new customers
of 23andMe and Pathway between March and July 2012.
Between March and July 2012, 3,900 23andMe customers
who had recently purchased PGT, and had completed the
company’s own informed consent process for participation
in research, were contacted directly by the company with
an email that provided an overview of the PGen Study
and an invitation to participate. The standard cost of
23andMe services at the time of study enrollment was
USD $99, although promotional discounts were some-
times available. Pathway recruited new customers for en-
rollment in the PGen Study in two ways: a banner
advertisement was placed on the Pathway website, and an
email was sent to approximately 30,000 members of
PatientsLikeMe, a health-based social networking site
[49]. Both approaches invited enrollment in the PGen
Study and offered Pathway’s health-related PGT services
for a subsidized cost of $25. Individuals who responded to
these invitations were not required to have their personal
physician order PGT; rather, these customers ordered
their own testing from the Pathway website, in a similar
fashion to 23andMe customers. Immediately after pur-
chasing PGT, Pathway customers were brought to a web-
page inviting them to participate in the PGen Study.
The PGen Study invitations included a link that directed
customers to the SSG-supported web-based survey sys-
tem. After affirming an online consent, participants agreed
to have their de-identified genetic risk information and
PGen Study survey responses shared with study investiga-
tors. After consent, participants were routed to the BL
survey. Reminder emails were sent 3 and 6 days after the
initial invitation to those customers who had not yet
responded.
Eligibility criteria for follow-up in the PGen Study in-
cluded completing the BL survey prior to viewing one’sPGT results and viewing one’s health-related PGT re-
sults within a defined period. Each company updated
SSG every 1 to 2 weeks post-enrollment with the status
of participants’ results reports, and those who completed
the BL survey after viewing their results were excluded
from follow-up.
Invitations to the 2 W survey were sent approximately
2 weeks after participants had accessed their results. If at
the start of the 2 W survey a participant indicated that they
had not viewed their health-related results, they were not
permitted to complete the follow-up surveys until they had
done so. Invitations to the 6 M survey were emailed to
eligible participants approximately 6 months after they
accessed their PGT results and eligibility for the 6 M survey
did not require completion of the 2 W survey. For both the
2 W and 6 M surveys, reminder emails were sent to eligible
non-responders 3 and 6 days after the initial invitation, and
reminder letters were mailed to non-responders who had
provided a mailing address in the BL survey.
We also designed an abbreviated survey directed to-
ward 6 M survey non-responders (6 M-NR) that con-
tained a subset of questions from the full 6 M survey
(Table 1). This 5 minute survey was administered after
completion of the 6 M survey data collection protocol,
and provided a way for non-responders to quickly an-
swer the most critical questions from the 6 M survey, to
identify reasons for non-response to the 6 M survey, and
to provide an additional opportunity to complete the
6 M survey. Upon completion of the 6 M-NR survey,
participants were invited to immediately continue on to
the full 6 M survey.
Participants were compensated for their participation
with Amazon.com electronic gift cards, receiving $10 for
completing the BL survey, $20 for the 2 W survey, and
$20 for either the 6 M or 6 M-NR survey (but not both).
Participant confidentiality
Maintaining participant confidentiality as data flowed
among researchers, PGT companies, and SSG was import-
ant to all concerned. The protocol for data flow was de-
signed to ensure that no single institution would have access
to all of three types of data: participant contact information,
survey responses, and genetic risk reports (Figure 2). Prior
to the start of the study, SSG created a set of master identi-
fier numbers (MIDs) and provided each company with suffi-
cient MIDs to accommodate all invitations to be sent to
potential participants. The companies maintained a link be-
tween the MID and the customers that were invited, so that
a link could later be made to their PGT results. When re-
spondents entered the SSG survey system, the MID was
passed in the web uniform resource locator (URL) and then
saved to the data during the consent process. When respon-
dents consented, the MID was then passed to the sample file
that SSG maintained (which included all participant contact
Figure 2 Data transfer and protection in the PGen Study. Heavily shaded boxes represent PGen Study team members; PGT customers/PGen
Study participants are represented by a striped box. The contents of each box represent the data types available to each party. Numbers indicate the
sequential steps involved in data transfer between PGen Study members (step 1 is italicized), and each arrow represents a one-way flow of data
between parties. Data in parentheses were embedded in the survey invitations and were not visible to participants. PGT, personal genomic testing;
MID, master identification number; SID, survey identification number; PID, personal identification number; BL, baseline; 2 W, 2 week; 6 M, 6 month.
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vidually track recruited participants through the survey
process. The SID was stored in SSG’s master sample file
along with the MID for later linking purposes. All respond-
ent communications, survey invitations, and survey access
points were then tracked and secured using the SID. The
purpose of this separate SID was to ensure that once the
final data were compiled, no individual (including respon-
dents) would have an ID that could uniquely identify some-
one in the final study dataset.
After administration of all three surveys, SSG provided
each company with a registry of MIDs for those cus-
tomers who consented and completed the BL survey;each company was then able to link individual PGT re-
ports to the MIDs of those who responded. Linked re-
ports and MIDs for each customer (stripped of any
contact information) were then sent to the PGen Study
data manager. Meanwhile, survey data linked with the
MID were sent directly from SSG to the PGen Study
data manager. The data manager subsequently merged
the survey data and risk reports using the MIDs.
Finally, the PGen Study data manager assigned each
participant a new, randomly generated primary identifi-
cation number (PID), ensuring that any party with access
to MID-labeled data could not create a link to the final
analytic data file. Any contact information provided by
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PID-labeled dataset containing linked, but de-identified,
survey data and risk reports was provided to the aca-
demic researchers.
Each PGT company was given a subset of the final data-
set containing only their own customers. It was agreed
that each company could freely use its own data; however,
all parties agreed not to use PGen Study data for competi-
tive marketing purposes. Although no explicit initial dis-
cussions were held about the use of company-specific data
for regulatory purposes, this possibility was discussed fol-
lowing receipt of the FDA Warning Letter by 23andMe,
and it was agreed that the companies could do so.
Data analysis
Baseline demographic characteristics were tabulated for
each sample of survey respondents. Chi-square tests and t-
tests were used to compare each follow-up survey sample
(2 W, 6 M, 6 M-NR) to BL survey responders to evaluate
the presence of differential attrition by follow-up time. An
analysis of substantive non-response bias was also per-
formed by randomly selecting six BL questions (addressing
behavioral, psychological, motivational, and health factors)
and then using t-tests and chi-squared tests to compare re-
sponses from participants who submitted both BL and 6 M
surveys to responses from participants who submitted a
BL, but not a 6 M survey.
Results
The BL, 2 W, and 6 M surveys comprised 240, 77, and
248 questions, respectively; however, all participants saw
only a subset of these questions, tailored to their PGT
experience and reflecting earlier responses. Median re-
sponse times among those who completed each survey
were 27 minutes for the BL survey, 22 minutes for the
2 W survey, and 32 minutes for the 6 M survey. Median
time to survey initiation after viewing one’s PGT results
was 17 days (2.4 weeks) for the 2 W survey and 190 days
(6.3 months) for the 6 M survey. Complete versions of
each survey are available online (Additional files 1, 2, 3
and 4).
Of 1,838 participants who began the BL survey, 1,648
completed the survey before accessing their PGT results
(Figure 3). Of these, 1,464 met eligibility criteria for
follow-up, including viewing of their PGT results within
the study period. Response rates were 71.4% at 2 W and
71.1% at 6 M. Nearly all of these responses were fully
completed surveys, resulting in a completion rate [50]
of 98.1% at 2 W and 95.7% at 6 M. Of those eligible for
follow-up, 933 (63.7%) submitted surveys at all three
time points, and 1,155 (78.9%) submitted at least one
follow-up survey. Among 6 M survey responders, 91.3%
agreed to be re-contacted about opportunities to par-
ticipate in future research, such as follow-up surveys orinterviews. The 6 M-NR increased response rates for
the 6 M survey: of the 455 non-responders to the 6 M
survey, 87 responded to the 6 M-NR survey invitation;
of these, 48 went on to submit a full 6 M survey.
A limited amount of demographic information was
available from the 3,900 23andMe customers invited to
the PGen Study to enable a comparison of invitees and par-
ticipants. The 947 eligible BL survey responders from
23andMe were more likely to be female (56.9% versus
47.8%; X2 = 34.4, P <0.0001), but were similar to the 3,900
invitees with respect to Latino ethnicity (5.6% of responders
versus 5.2% of invitees; X2 = 0.3, P =0.58), and age (50.9 ±
16.1 years versus 50.1 ± 15.8 years; t =1.4, P =0.16). A com-
parison of invited and enrolled Pathway customers would
have required demographic data from the PatientsLikeMe
members who were invited to participate and these data
were not available to the PGen Study team.
Table 2 summarizes the demographic characteristics
of PGen Study respondents for each survey. t-Tests and
chi-squared tests demonstrated no significant differences
(P >0.05) in demographic characteristics between eligible
BL survey responders and either 2 W responders or 6 M
responders. 6 M-NR survey responders differed from eli-
gible BL survey responders only with respect to PGT com-
pany in that 6 M-NR survey responders were significantly
less likely than BL survey responders to have had their
testing through 23andMe (49.4% 23andMe customers at
6 M-NR versus 64.7% at BL; X2 = 8.8, P =0.003). The final
6 M responder sample, however, including those recruited
to the 6 M survey following completion of the 6 M-NR
survey, did not significantly differ from eligible BL re-
sponders with respect to PGT company (62.4% 23andMe
customers at 6 M versus 64.7% at BL; X2 = 1.4, P =0.24).
Relative to the 2013 United States population [51], PGen
Study BL survey responders were older (median age
47.0 years versus 37.5 years), more likely to be female
(61.2% versus 50.8%), less likely to be non-white (15.7%
versus 22.3%) or Hispanic/Latino (5.5% versus 17.1%),
more highly educated (78.2% college graduates versus
28.5%), slightly more likely to be married (54.4% versus
48.0%), and more likely to have health insurance coverage
(94.7% versus 85.5%).
Six BL survey questions were randomly selected for
the non-response bias analysis. These questions evalu-
ated, respectively, motivations for undergoing PGT; be-
liefs about PGT utility; perceived autonomy in health
care decision making; recent history of anxiety; per-
ceived risk of Alzheimer’s disease; and body mass index
(BMI). Chi-squared tests and t-tests to compare
responses to each question demonstrated no significant
differences between the 1,042 participants who com-
pleted both BL and 6 M surveys and the 422 partici-
pants who completed the BL but not 6 M survey
(all P >0.05).
Figure 3 PGen Study data collection strategy and enrollment results. Heavily shaded boxes represent data collection points; lightly shaded
boxes represent loss-to-follow-up or exclusion criteria.
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Empirical data on the PGT customer experience is
important to a range of stakeholders, but is difficult toobtain without explicit cooperation between researchers
and industry partners. Here we describe the design and
implementation of the PGen Study, a longitudinal study
Table 2 Demographic characteristics of PGen Study participants
BL survey responders
eligible for follow-up
2 W survey responders 6 M survey responders 6 M-NR survey responders
n 1,464 1,046 1,042 86
Mean age (±SD; range) 47.5 (15.5; 19-94) 46.7 (15.7; 19-91) 46.9 (15.6; 19-94) 47.8 (15.5; 23-94)
Mean self-reported health (±SD)a 2.49 (1.01) 2.50 (1.0) 2.49 (1.0) 2.60 (1.1)
Female (%) 61.2 60.1 60.2 70.9
Annual income (%)
<$40,000 16.8 17.5 17.1 18.4
$40,000-$99,999 38.8 38.0 38.8 40.2
$100,000-$199,999 31.7 32.2 31.3 31.0
≥$200,000 12.7 12.3 12.8 10.4
Education (%)
<College degree 21.8 21.0 20.4 25.3
College degree 30.6 30.2 30.0 34.5
Some graduate school 35.0 35.6 36.4 28.7
Doctoral degree 12.6 13.2 13.2 11.5
Marital status (%)
Single 19.2 19.6 19.9 13.8
Long-term partner 13.7 15.2 14.7 13.8
Married 54.4 52.5 52.5 57.5
Widowed/divorced/separated 12.7 12.7 12.9 14.9
Health insurance (%) 94.7 95.5 95.3 96.6
United States residency (%) 97.9 98.0 98.2 97.7
Non-white (%) 15.7 14.7 14.2 10.3
Hispanic/Latino (%) 5.5 4.6 5.1 3.5
23andMe customers (%) 64.7 60.4 62.4 49.4
aSelf-reported health was measured on a 5-point scale from 1 (poor) to 5 (excellent).
SD, standard deviation.
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PGT companies, and present the surveys themselves
along with initial data on the cohort. Careful and trans-
parent navigation of the industry-academic partnership
was important throughout the design and data collec-
tion stages of the PGen Study, and will continue to be
important as we further analyze and report these data.
Response rates surpassed 70% at both short-term and
long-term follow-up, and were achieved by optimizing
the participant experience through a user-friendly sur-
vey design. Although minimization of participant bur-
den is always a consideration in study design, here it
was particularly important to company representatives
that their customers not have a negative research ex-
perience. In surveying PGT customers who had ordered
testing online, the ability to direct respondents to a
web-based survey via email invitation was also key to
obtaining high response rates. The value of following up
non-respondents with an alternative invitation strategywas also demonstrated, as use of the 6 M-NR survey
reduced overall attrition rates, and did so without
evidence of differential attrition, a major source of con-
cern in online longitudinal measurement [52,53]. Ultim-
ately, we achieved a set of surveys that collectively
administered nearly 600 questions while maintaining
high response, completion, and retention rates.
To ensure that data collection did not interfere with the
user experience of PGT, the PGen Study integrated data
collection into the commercial PGT process. Communica-
tion and cooperation between the study collaborators was
essential, and enabled us to dynamically assess participant
eligibility throughout the data collection phase and ensure
accurate timing of data collection based on date of results
delivery.
Through these features, the PGen Study has potentially
achieved a more naturalistic study of the PGT experience
than previous longitudinal research on PGT users. For ex-
ample, the Scripps Genomic Health Initiative (SGHI) also
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sidized testing was provided on the condition of consent
to the SGHI, participants could ask study investigators
questions about PGT at the time of sample collection, and
participants were recruited from among employees of a
medical research institute focused on personalized
healthcare.
In the PGen Study, the task of linking a participant’s
survey responses with their individual genetic results was
accomplished by leveraging the expertise of SSG in large-
scale data management, and by creating a tightly
controlled data transfer process between study partners.
Access to participants’ actual PGT results has been avail-
able in several previous longitudinal studies of PGT,
including the SGHI study, the Multiplex Initiative (Multi-
plex) [24], and the Coriell Personalized Medicine Collabor-
ation [54]. The Multiplex model, however, included PGT for
only eight conditions, and was provided to members of a
large integrated health system, who received educational
counseling with their results. The Coriell model integrated
PGT into clinical care through patient education, optional
genetic counseling, and physician review of results.
The PGen Study data transfer process maintained par-
ticipant confidentiality by ensuring that neither company
had access to data on the other company’s customers,
and that no company had access to identifiable survey
data for its own customers. This is the first study of
PGT to rely on a three-party data transfer model, and is
the only academic study in the field of clinical genetics
to engage a commercial genetic testing company and
third-party research firm in such a way.
A single, comprehensive, yet fully de-identified PGen
Study dataset with longitudinal data on over 1,000 ac-
tual PGT customers is now available. A sample of PGT
customers is not expected to be a random sample of the
US population, and in fact, PGen Study participants dif-
fered from the general population with respect to age
and sex distribution, ethnicity, education level, and
health insurance coverage. At the same time, PGen
Study participants represented a wide distribution of in-
come and education levels, marital status, and ages,
with a sizeable proportion (approximately 15%) being of
non-white ethnicity. These features of the PGen Study
cohort will facilitate future subgroup analyses.
The PGen Study team faced the challenge of engaging
two PGT companies in a way that maintained the uncen-
sored pursuit of research questions, yet ensured that
neither company would be promoted or slighted, and
allowed all parties the opportunity to continue to have a
voice in ongoing research and analysis. All parties agreed
that none of the researchers would engage in comparisons
of the two PGT companies, particularly with respect to
endpoints that could be relevant to commercial marketing
(for example, customer satisfaction). This agreement hasled to considerable discussion within the study team about
when comparison of participants between companies may
be appropriate on statistical grounds, and we expect to re-
visit this question with each new analysis of PGen Study
data.
These subjects have required an ongoing and trans-
parent dialogue between the principal investigators
and PGT company scientists. However, careful plan-
ning of the PGen Study has thus far been conducted
through a collegial relationship between study mem-
bers and a shared vision for the study, with discus-
sions and negotiations to date being respectful and
fruitful. All parties have acknowledged the potential
for conflicts of interest from the outset, and have
worked together to maintain rigorous data collection
and analysis standards.
Benefits of the PGen Study as a data source include its
large and diverse sample; wide-ranging source popula-
tion; longitudinal design; high response rates; expansive
set of survey questions; inclusion of participants’ PGT
results; and the high proportion of participants agreeing
to future follow-up. Limitations include those inherent
to voluntary study enrollment, such as the potential for
selection bias in restricting the sample to voluntary
enrollees and in excluding from longitudinal analyses
those who did not complete follow-up surveys.
In addition, our findings are potentially generalizable
only to other PGT customers utilizing a DTC model
similar to those of 23andMe and Pathway at the time
of the study, and not to individuals who undergo
physician-mediated PGT, who have not voluntarily
sought PGT, or who have obtained clinical genetic test-
ing. Our decision to focus on the DTC PGT was, how-
ever, intentional: because the DTC model is the most
extreme version of PGT (with respect to its dissimilarity
to clinical genetic testing), it is the most likely to reveal
evidence of harm from PGT, and would provide the
greatest support for PGT if evidence of consumer bene-
fit is observed.
A related but separate limitation is the fact that Path-
way participants were recruited through the offer of
low-cost subsidized testing, whereas 23andMe partici-
pants were not. Pathway participants in our study may
differ in meaningful ways from both typical Pathway
participants and 23andMe participants who paid more
for their testing. Future analyses of PGen Study data will
investigate testing cost and its impact on motivations
and test satisfaction, and results will be stratified by
testing company where appropriate.
Our data collection was completed prior to the FDA’s
Warning Letter to 23andMe. However, we recognize
that the FDA Warning Letter represents a significant
shift in the regulation of PGT, and one that will surely
impact public opinion and utilization of these services if
Carere et al. Genome Medicine 2014, 6:96 Page 10 of 11
http://genomemedicine.com/content/6/12/96and when they are reinstated. Moreover, the field of
PGT, including its technology and service models,
evolves quickly, and major changes to the industry
could lessen the relevance of PGen Study data over
time.
Conclusions
We have reported on the design, implementation, and
participant characteristics of a new prospective cohort
study of PGT customers, highlighted state-of-the-art on-
line survey methods capable of both minimizing costs and
maximizing data integrity, and detailed a data security
protocol that ensures participant confidentiality while per-
mitting ease of data transfer between academic and indus-
try partners. For those developing studies of new health
technologies, particularly ones marketed directly to pri-
vate customers, the PGen Study may serve as a model of
successful industry engagement that maintains academic
independence. For stakeholders in the debate surrounding
PGT, the PGen Study provides a large and comprehensive
data source, with high completion and response rates, that
is ripe for further interrogation.
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